Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis.
about
Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.Identification of sarilumab pharmacodynamic and predictive markers in patients with inadequate response to TNF inhibition: a biomarker substudy of the phase 3 TARGET study.Delayed Treatment Acceleration in Patients with Rheumatoid Arthritis Who Have Inadequate Response to Initial Tumor Necrosis Factor Inhibitors: Data from the Corrona Registry.
P2860
Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Outcomes of tumor necrosis fac ...... nts with rheumatoid arthritis.
@en
Outcomes of tumor necrosis fac ...... nts with rheumatoid arthritis.
@nl
type
label
Outcomes of tumor necrosis fac ...... nts with rheumatoid arthritis.
@en
Outcomes of tumor necrosis fac ...... nts with rheumatoid arthritis.
@nl
prefLabel
Outcomes of tumor necrosis fac ...... nts with rheumatoid arthritis.
@en
Outcomes of tumor necrosis fac ...... nts with rheumatoid arthritis.
@nl
P2093
P2860
P1476
Outcomes of tumor necrosis fac ...... nts with rheumatoid arthritis.
@en
P2093
Benjamin Chastek
Chieh-I Chen
Jeffrey R Curtis
Laura K Becker
Puneet Mahajan
P2860
P304
P356
10.1080/13696998.2016.1275653
P407
P577
2016-12-23T00:00:00Z